{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:41:28Z","timestamp":1783021288783,"version":"3.54.6"},"reference-count":29,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"Sp. 1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["Biomed."],"abstract":"<jats:p>Introducci\u00f3n. Las infecciones adquiridas en la comunidad suponen una carga considerable para los sistemas de salud y son causadas por diversos agentes pat\u00f3genos que pueden presentar distintos grados de gravedad. El aumento de la resistencia microbiana complica el tratamiento, lo que destaca la necesidad de nuevas terapias. La omadaciclina, un nuevo antibi\u00f3tico, tiene una actividad de amplio espectro contra agentes pat\u00f3genos tanto grampositivos como gramnegativos, en particular los implicados en infecciones adquiridas en la comunidad.Objetivo. Evaluar la eficacia y seguridad de la omadaciclina para el tratamiento de infecciones adquiridas en la comunidad.Materiales y m\u00e9todos. Se buscaron estudios aleatorizados y no aleatorizados sobre omadaciclina para infecciones adquiridas en la comunidad, en PubMed, Embase y Cochrane, sin restricciones de tiempo. Los resultados primarios fueron el \u00e9xito cl\u00ednico al final del tratamiento y la evaluaci\u00f3n posterior al tratamiento. Los resultados secundarios incluyeron el riesgo de eventos adversos. El an\u00e1lisis estad\u00edstico se hizo con el software R. Resultados. Se analizaron datos de diez estudios que incluyeron 1666 pacientes y que abordaron infecciones como neumon\u00eda, infecciones de heridas, celulitis, abscesos importantes, \u00falceras de las extremidades inferiores, erisipela, cistitis e infecciones \u00f3seas o articulares. El an\u00e1lisis mostr\u00f3 una tasa de \u00e9xito cl\u00ednico del 90 % (1138 de 1264 pacientes; IC95%: 88 - 91) al final del tratamiento y del 84 % (1288 de 1534 pacientes; IC95%: 82 - 86) postratamiento. Ocurrieron eventos adversos en el 45 % de los casos (747 de 1662; IC95%: 32 - 59), con un 18 % que experimentaron problemas gastrointestinales (181 de 1008; IC95%: 13 - 24). La tasa de mortalidad fue del 0 % (0,8%) (13 pacientes; IC95%: 0 - 1).Conclusi\u00f3n. La omadaciclina es una opci\u00f3n prometedora para el tratamiento de las infecciones adquiridas en la comunidad.<\/jats:p>","DOI":"10.7705\/biomedica.7814","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:54:25Z","timestamp":1783004065000},"page":"47-59","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Omadacycline for community-acquired infections: A systematic review and single-arm meta-analysis","Omadaciclina para infecciones adquiridas en la comunidad: una revisi\u00f3n sistem\u00e1tica y un metan\u00e1lisis de un solo brazo"],"prefix":"10.7705","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3186-2589","authenticated-orcid":false,"given":"Wellgner","family":"Fernandes Oliveira Amador","sequence":"first","affiliation":[{"name":"Departamento de Medicina, Universidade Federal de Campina Grande, Cajazeiras, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4222-4276","authenticated-orcid":false,"given":"Cain\u00e3","family":"Ara\u00fajo Saraiva","sequence":"additional","affiliation":[{"name":"Departamento de Medicina, Universidade Federal de Campina Grande, Cajazeiras, Brasil"},{"name":"Departamento de Medicina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6011-7943","authenticated-orcid":false,"given":"Pandora","family":"Elo\u00e1 Oliveira Fonseca","sequence":"additional","affiliation":[{"name":"Departamento de Medicina, Universidade Federal de Campina Grande, Cajazeiras, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-4755","authenticated-orcid":false,"given":"S\u00e1vio","family":"Benvindo Ferreira","sequence":"additional","affiliation":[{"name":"Departamento de Medicina, Universidade Federal de Campina Grande, Cajazeiras, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4444","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"161931","unstructured":"World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2022. Geneva: World Health Organization; 2022. p. 82."},{"key":"161932","doi-asserted-by":"crossref","unstructured":"Cassini A, H\u00f6gberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibioticresistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect Dis. 2019;19:56-66. https:\/\/doi.org\/10.1016\/s1473-3099(18)30605-4","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"161933","doi-asserted-by":"crossref","unstructured":"Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, et al. Omadacycline: A novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80:285-313. https:\/\/doi.org\/10.1007\/s40265-020-01257-4","DOI":"10.1007\/s40265-020-01257-4"},{"key":"161934","doi-asserted-by":"crossref","unstructured":"Markham A, Keam SJ. Omadacycline: First global approval. Drugs. 2018;78:1931-7. https:\/\/doi.org\/10.1007\/s40265-018-1015-2","DOI":"10.1007\/s40265-018-1015-2"},{"key":"161935","doi-asserted-by":"crossref","unstructured":"Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs: 2018-2019. Discoveries (Craiova). 2019;7:e102. https:\/\/doi.org\/10.15190\/d.2019.15","DOI":"10.15190\/d.2019.15"},{"key":"161936","doi-asserted-by":"crossref","unstructured":"Anderson R, Feldman C. The global burden of community-acquired pneumonia in adults, encompassing invasive pneumococcal disease and the prevalence of its associated cardiovascular events, with a focus on pneumolysin and macrolide antibiotics in pathogenesis and therapy. Int J Mol Sci. 2023;24:11038. https:\/\/doi.org\/10.3390\/ijms241311038","DOI":"10.3390\/ijms241311038"},{"key":"161937","doi-asserted-by":"crossref","unstructured":"Villano S, Steenbergen J, Loh E. Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421-34. https:\/\/doi.org\/10.2217\/fmb-2016-0100","DOI":"10.2217\/fmb-2016-0100"},{"key":"161938","doi-asserted-by":"crossref","unstructured":"Singh KV, Murray BE. Efficacy of Omadacycline against Escherichia coli in a mouse urinary tract infection model. Antimicrob Agents Chemother. 2021;65:e0026921. https:\/\/doi.org\/10.1128\/aac.00269-21","DOI":"10.1128\/AAC.00269-21"},{"key":"161939","doi-asserted-by":"crossref","unstructured":"Singh KV, \u00c1rias CA, Murray BE. Efficacy of Omadacycline against multidrug-resistant enterococcus faecium strains in a mouse peritonitis model. 2021;65:e0070921. https:\/\/doi.org\/10.1128\/aac.00709-21","DOI":"10.1128\/AAC.00709-21"},{"key":"161940","doi-asserted-by":"crossref","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","DOI":"10.1186\/2046-4053-4-1"},{"key":"161941","doi-asserted-by":"crossref","unstructured":"El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: A retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023;67:e0082423. https:\/\/doi.org\/10.1128\/aac.00824-23","DOI":"10.1128\/aac.00824-23"},{"key":"161942","doi-asserted-by":"crossref","unstructured":"Mingora CM, Bullington W, Faasuamalie PE, Levin A, Porter G, Stadnick R, et al. Longterm safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections. Open Forum Infect Dis. 2023;10:ofad335. https:\/\/doi.org\/10.1093\/ofid\/ofad335","DOI":"10.1093\/ofid\/ofad446"},{"key":"161943","unstructured":"Paratek Pharmaceuticals Inc. A randomized, double-blinded, adaptive phase 2 study to evaluate the safety and efficacy of oral omadacycline and oral nitrofurantoin in the treatment of female adults with cystitis. Report No.: NCT03425396. Accessed: December 31, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03425396"},{"key":"161944","unstructured":"Paratek Pharmaceuticals Inc. A randomized, evaluator-blinded, phase 3 study to compare the safety and efficacy of PTK 0796 with linezolid in the treatment of adults with complicated skin and skin structure infection. Report No.: NCT00865280. Accessed: December 31, 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00865280"},{"key":"161945","unstructured":"Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:5650-4. https:\/\/doi.org\/10.1128\/AAC.01548-12"},{"key":"161946","doi-asserted-by":"crossref","unstructured":"O\u2019Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528-38. https:\/\/doi.org\/10.1056\/NEJMoa1808843","DOI":"10.1056\/NEJMoa1800170"},{"key":"161947","doi-asserted-by":"crossref","unstructured":"O\u2019Riordan W, C\u00e1rdenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): A phase 3, double-blind, multicentre, randomised, controlled, noninferiority trial. Lancet Infect Dis. 2019;19:1080-90. https:\/\/doi.org\/10.1016\/S1473-3099(19)30305-4","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"161948","doi-asserted-by":"crossref","unstructured":"Overcash JS, Bhiwandi P, Garrity-Ryan L, Steenbergen J, Bai S, Chitra S, et al. Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: Results from a phase 1b study. Antimicrob Agents Chemother. 2019;63:e02083-18. https:\/\/doi.org\/10.1128\/AAC.02083-18","DOI":"10.1128\/AAC.02083-18"},{"key":"161949","doi-asserted-by":"crossref","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517-27. https:\/\/doi.org\/10.1056\/NEJMoa1809862","DOI":"10.1056\/NEJMoa1800201"},{"key":"161950","doi-asserted-by":"crossref","unstructured":"Wang DX, Xiao LX, Deng XY, Deng W. Omadacycline for the treatment of severe pneumonia caused by Chlamydia psittaci complicated with acute respiratory distress syndrome during the COVID-19 pandemic. Front Med (Lausanne). 2023;10:1207534. https:\/\/doi.org\/10.3389\/fmed.2023.1207534","DOI":"10.3389\/fmed.2023.1207534"},{"key":"161951","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"161952","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"161953","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55-61. https:\/\/doi.org\/10.1002\/jrsm.1411","DOI":"10.1002\/jrsm.1411"},{"key":"161954","doi-asserted-by":"crossref","unstructured":"Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e18426. https:\/\/doi.org\/10.1097\/MD.0000000000018426","DOI":"10.1097\/MD.0000000000018426"},{"key":"161955","doi-asserted-by":"crossref","unstructured":"Liang W, Yin H, Chen H, Xu J, Cai Y. Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: A meta-analysis of randomized controlled trials. BMC Infect Dis. 2024;24:219. https:\/\/doi.org\/10.1186\/s12879-024-08044-0","DOI":"10.1186\/s12879-024-09097-3"},{"key":"161956","doi-asserted-by":"crossref","unstructured":"Lin F, He R, Yu B, Deng B, Ling B, Yuan M. Omadacycline for treatment of acute bacterial infections: A meta-analysis of phase II\/III trials. BMC Infect Dis. 2023;23:232. https:\/\/doi.org\/10.1186\/s12879-023-08140-5","DOI":"10.1186\/s12879-023-08212-0"},{"key":"161957","doi-asserted-by":"crossref","unstructured":"Silva PG, Filho LA, Ismael PF, Victoria VES, Alexandre TM, Larissa SM. Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options. Medwave. 2023;23:e2719. https:\/\/doi.org\/10.5867\/medwave.2023.11.2719","DOI":"10.5867\/medwave.2023.11.2719"},{"key":"161958","unstructured":"Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59:864-71. https:\/\/doi.org\/10.1128\/AAC.04293-14"},{"key":"161959","doi-asserted-by":"crossref","unstructured":"Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P. Early clinical response as a predictor of late treatment success in patients with acute bacterial skin and skin structure infections: Retrospective analysis of 2 randomized controlled trials. Clin Infect Dis. 2017;64:214-7. https:\/\/doi.org\/10.1093\/cid\/ciw721","DOI":"10.1093\/cid\/ciw750"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7814\/5808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7814\/5808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:03:13Z","timestamp":1783018993000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/7814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":29,"journal-issue":{"issue":"Sp. 1","published-online":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.7814","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2026-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Art\u00edculos originales","name":"content_type","label":"Content Type"}]}}